GlassScriptPhysician profile
Shree Mulay
NPI 1548671845
$55,624.95
in general payments reported to CMS, 2019-2025
28 companies · $21K in 2025
The $21K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $272 · 2021: $832 · 2022: $1,583 · 2023: $16K · 2024: $16K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $25K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $6,667 · Travel and Lodging: $2,301 · Consulting Fee: $1,500 · Education: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $25,060.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,850.00 |
| Food and Beverage | $6,667.29 |
| Travel and Lodging | $2,300.92 |
| Consulting Fee | $1,500.00 |
| Education | $267.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18,306.03 | 2024-2025 | Krystexxa, Tavneos |
| Scpharmaceuticals INC. | $14,984.98 | 2023-2025 | |
| Horizon Therapeutics Plc | $12,400.71 | 2022-2023 | Krystexxa |
| Daxor Corporation | $2,722.86 | 2023-2025 | Bva-100 |
| Bayer Healthcare Pharmaceuticals INC. | $1,564.13 | 2021-2025 | |
| Nuwellis, INC. | $1,257.42 | 2020-2024 | Aquadex Smartflow Console |
| Astrazeneca Pharmaceuticals LP | $752.22 | 2021-2025 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $697.65 | 2019-2025 | Jynarque, Voyxact |
| Renalytix Ai, INC. | $303.21 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Ardelyx, INC. | $294.42 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Calliditas Therapeutics US INC. | $275.15 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $256.63 | 2023-2024 | Auryxia, Vafseo |
| Fresenius USA Marketing, INC. | $248.31 | 2020-2025 | Velphoro, Velphoro |
| Travere Therapeutics, INC. | $242.82 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $212.85 | 2022-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $160.20 | 2022 | |
| Abiomed | $149.17 | 2024 | Impella |
| Vifor Pharma, INC. | $135.62 | 2022-2024 | Veltassa, Korsuva |
| Glaxosmithkline, LLC. | $119.97 | 2022-2023 | Benlysta |
| Opko Pharmaceuticals, LLC | $107.80 | 2024-2025 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.22 | 2022-2024 | Jardiance |
| Bard Peripheral Vascular, INC. | $77.69 | 2019 | |
| Novo Nordisk INC | $72.28 | 2025 | |
| Baxter Healthcare | $68.16 | 2019 | |
| Nxstage Medical, INC. | $65.19 | 2019 | |
| Merck Sharp & Dohme LLC | $28.17 | 2022 | |
| Apellis Pharmaceuticals, INC. | $19.31 | 2025 | Empaveli |
| Siemens Medical Solutions USA, INC. | $18.78 | 2023 | Dimension Exl With Lm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shree Mulay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.